Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced
\nNSCLC whose disease has progressed after:<\/p>\n
Lorviqua25 mg film-coated tablets
\nTo access Lorviqua tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Lorviqua (lorlatinib) is a medicine indicated for the treatment of previously treated patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).\u00a0The medicine is marketed in the USA under the brand name Lorbrena, and in the EU under the brand name Lorviqua. We can help you obtain Lorviqua (lorlatinib) on our website.<\/p>\n
Disease Indications-Lung Cancer If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cLorviqua tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Pfizer Limited
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n